Skip to main content
康乐卫士 logo

康乐卫士 — Investor Relations & Filings

Ticker · 920575 ISIN · CNE1000059W8 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 537 across all filing types
Latest filing 2025-03-26 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920575

About 康乐卫士

https://www.klws.com/

Beijing Health Guard Biotechnology Inc. is a clinical-stage biopharmaceutical company specializing in the research, development, and commercialization of innovative recombinant human vaccines. The company leverages advanced structural biology and protein engineering platforms to create a diverse pipeline of vaccine candidates. Its primary focus includes the development of high-valent human papillomavirus (HPV) vaccines, with its trivalent and nine-valent candidates in late-stage clinical trials. Additionally, the company is advancing candidates for respiratory syncytial virus (RSV), shingles, and other infectious diseases. By utilizing recombinant protein technology, Health Guard aims to provide high-quality, affordable immunization solutions to address significant unmet medical needs. Its technical expertise encompasses antigen design, high-throughput screening, and large-scale manufacturing processes.

Recent filings

Filing Released Lang Actions
关于接受控股股东财务资助暨关联交易的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a financial transaction where the company's controlling shareholder provides financial support through a loan. It details the terms of the loan, the decision-making process by the board and independent directors, and confirms compliance with relevant regulations. The document is relatively short (2474 characters) and focuses on the announcement of a financing event rather than providing comprehensive financial statements or detailed financial analysis. It does not contain quarterly or annual financial results, nor is it a transcript or a report of voting results. The content fits best under the category of Capital/Financing Update (CAP), as it updates on company fundraising and financing activities.
2025-03-26 Chinese
关于三价HPV疫苗被纳入优先审评品种名单的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Beijing Kangle Weishi Biotechnology Co., Ltd. regarding their trivalent HPV vaccine being included in the priority review list by the National Medical Products Administration's Center for Drug Evaluation (CDE). It provides details about the vaccine, the application dates, regulatory context, and potential impact on the company. The document is relatively short (1431 characters) and serves as a regulatory announcement about a product development milestone and regulatory status update. It does not contain financial statements, management discussion, or detailed financial data. It is not a full report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or earnings release. It is also not a report publication announcement since it contains substantive information about the regulatory status. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-03-20 Chinese
关于回复北京证券交易所问询函的公告
Regulatory Filings Classification · 95% confidence The document is a detailed response to an inquiry letter from the Beijing Stock Exchange regarding the company's loan application, R&D progress, debt repayment plans, asset pledges, management changes, and insider trading checks. It includes extensive financial and operational details, loan repayment schedules, and risk assessments. The document is not a full annual or quarterly report but a regulatory response to a specific inquiry. It is not a simple announcement or certification but a substantive regulatory filing addressing multiple compliance and disclosure requirements. Therefore, it fits best under Regulatory Filings (RNS). The document length (7742 characters) and content confirm it is not a brief announcement or a full financial report but a comprehensive regulatory disclosure.
2025-03-20 Chinese
关于重组十五价人乳头瘤病毒疫苗（大肠埃希菌）进入Ⅱ期临床试验的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Beijing Kangle Weishi Biotechnology Co., Ltd. regarding the initiation of Phase II clinical trials for a recombinant 15-valent human papillomavirus vaccine. It includes details about the clinical trial registration, cooperation with another company, and risk disclosures. The document is short (1243 characters) and focuses on a clinical development update rather than financial results, management changes, or regulatory filings. It does not contain financial statements or detailed financial data, nor is it a report or presentation. It is an announcement about a clinical trial progress, which fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2025-03-18 Chinese
第五届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fifth Supervisory Board of Beijing Kangle Weishi Biotechnology Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on approval of a loan application by a subsidiary and related guarantees, with no financial statements or detailed financial analysis included. The document is an official announcement of board/management decisions rather than a full report or financial disclosure. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a regulatory filing or a report publication announcement since it contains substantive meeting resolution content. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short (1137 characters), consistent with a meeting resolution announcement rather than a full report.
2025-03-13 Chinese
副董事长辞职公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the Vice Chairman of the Board and a member of the Board's Strategic Committee. It details the resignation date, shareholding information, reasons for resignation, and the impact on the company's board composition and operations. There is no financial data, no mention of financial results, no regulatory certifications, or report attachments. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2025-03-13 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.